After REMS: An Interview With Amgen’s Paul Seligman
Executive Summary
Health care reform means a lot of things for the pharmaceutical industry. Will it also mean the end of REMS? The former head of FDA’s drug safety office thinks that is a question worth asking.
You may also be interested in...
Drug Safety: FDA Pushes To Publicly Release REMS Assessments, Says It Will Improve Plan Design
Proposal would allow stakeholders to see data on REMS goals like provider training and the US FDA’s conclusions about their effectiveness.
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
FDA’s use of REMS continues to fall to almost undetectable levels, with the agency using the safety tools just a handful of times in the sixth full year of the program. REMS are now very much the exception and not the rule for new products – but still a very important exception.
End Of ‘Phase I’: The Case To Re-Name First-In-Human Oncology Trials
US FDA’s push to re-think oncology dosing should begin by renaming the initial human trials to de-emphasize toxicity, a National Cancer Institute official suggests.